Pitolisant

{{chembox-lat | Verifiedfields = | verifiedrevid = 464208162 |ImageFile=BF2649_structure.png |ImageSize=200px |IUPACName=1-{3-[3-(4-hlorofenil)propoksi]propil}piperidin |OtherNames= BF2.649 |Section1=! colspan=2 style="background: #f8eaba; text-align: center;" |Identifikacija

|-

|

|

|-

|

3D model (Jmol)

|

|-



| ChemSpider

|

|-





|

|

|-


| align="center" colspan="2" | |-

| colspan="2" |

  • Clc1ccc(cc1)CCCOCCCN2CCCCC2

|- |Section2=! colspan=2 style="background: #f8eaba; text-align: center;" |Svojstva

|-

|

| C17H26ClNO

|- | Molarna masa

| 295,846 g/mol

|- |Section3= }}

Pitolisant (INN) ili tiprolisant (USAN) je inverzni agonist/antagonist histaminskog receptora koji je selektivan za H3 receptor.[3] On ima stimulantne i nootropne efekte u životinjskim studijama,[4] i može da ima nekoliko potencijalnih medicinskih primena. Istražen je za tretman narkolepsije, i za tu indikaciju mu je odobren status orfan leka u EU i SAD.[5][6] On je u kliničkim ispitivanjima za šizofreniju i Parkinsonova bolest.[6][7][8]

Pitolisant je razvijen nakon otkrića H3 receptora.[9] Pitolisant je prvi inverzni agonist H3 receptora sa kliničkom primenom.

Reference

  1. ^ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today. 15 (23-24): 1052—7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003.  уреди
  2. ^ Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1. 
  3. ^ Celanire S, Wijtmans M, Talaga P, Leurs R, de Esch IJ (2005). „Keynote review: histamine H3 receptor antagonists reach out for the clinic”. Drug Discov. Today. 10 (23–24): 1613—27. PMID 16376822. doi:10.1016/S1359-6446(05)03625-1. 
  4. ^ -{Ligneau X, Perrin D, Landais L, Camelin JC, Calmels TP, Berrebi-Bertrand I, Lecomte JM, Parmentier R, Anaclet C, Lin JS, Bertaina-Anglade V, la Rochelle CD, d'Aniello F, Rouleau A, Gbahou F, Arrang JM, Ganellin CR, Stark H, Schunack W, Schwartz JC. BF2.649 [13-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: Preclinical pharmacology. Ligneau, X.; Perrin, D.; Landais, L.; Camelin, J. C.; Calmels, T. P.; Berrebi-Bertrand, I.; Lecomte, J. M.; Parmentier, R.; Anaclet, C.; Lin, J. S.; Bertaina-Anglade, V.; La Rochelle, C. D.; d'Aniello, F.; Rouleau, A.; Gbahou, F.; Arrang, J. M.; Ganellin, C. R.; Stark, H.; Schunack, W.; Schwartz, J. C. (јануар 2007). „BF2.649 1-{3-3-(4-Chlorophenyl)propoxypropyl}piperidine, hydrochloride, a nonimidazole inverse agonist/Antagonist at the human histamine H3 receptor: Preclinical pharmacology”. Journal of Pharmacology and Experimental Therapeutics. 320 (1): 365—75. PMID 17005916. doi:10.1124/jpet.106.111039. 
  5. ^ Lin JS, Dauvilliers Y, Arnulf I, Bastuji H, Anaclet C, Parmentier R, Kocher L, Yanagisawa M, Lehert P, Ligneau X, Perrin D, Robert P, Roux M, Lecomte JM, Schwartz JC (април 2008). „An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients”. Neurobiology of Disease. 30 (1): 74—83. PMID 18295497. doi:10.1016/j.nbd.2007.12.003. 
  6. ^ а б „Prous Science: Molecule of the Month September 2011”.  „Архивирана копија”. Архивирано из оригинала 26. 09. 2011. г. Приступљено 19. 07. 2012. 
  7. ^ Ligneau, X.; Landais, L.; Perrin, D.; Piriou, J.; Uguen, M.; Denis, E.; Robert, P.; Parmentier, R.; Anaclet, C.; Lin, J. S.; Burban, A.; Arrang, J. M.; Schwartz, J. C. (април 2007). „Brain histamine and schizophrenia: Potential therapeutic applications of H3-receptor inverse agonists studied with BF2.649.” (PDF). Biochemical Pharmacology. 73 (8): 1215—24. PMID 17343831. doi:10.1016/j.bcp.2007.01.023. 
  8. ^ Stocking EM, Letavic MA (2008). „Histamine H3 antagonists as wake-promoting and pro-cognitive agents”. Current Topics in Medicinal Chemistry. 8 (11): 988—1002. PMID 18673168. doi:10.2174/156802608784936728. 
  9. ^ Schwartz, Jean-Charles (2011). „The histamine H3 receptor: From discovery to clinical trials with pitolisant”. British Journal of Pharmacology. 163 (4): 713—721. PMC 3111674 Слободан приступ. PMID 21615387. doi:10.1111/j.1476-5381.2011.01286.x. 
Pitolisant на Викимедијиној остави.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.